Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Diabetic Macular Edema
Interventions: RO7497372; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 34 more

Conditions: Healthy
Interventions: LY3154207 Capsule, LY3154207 Tablet, Placebo, Fluconazole Tablet; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Disability Physical, Cognitive Impairment
Interventions: Modified FE-SaLiR, Unmodified Chinese Medicine Exercise, Active Control; Behavioral
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Virtual Reality
Interventions: Pain Rehabilitation Virtual Reality (PRVR), Standard Physiotherapy Rehabilitation (SPR); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Menlo Park, California • Palo Alto, California

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis
Interventions: Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Eating Disorder Symptom, Body Image Disturbance
Interventions: Mirror exposure and text prompt responses; Behavioral
Lead sponsor: Union College, New York; Other
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Albany, New York • Schenectady, New York

Conditions: Liver Cancer
Interventions: image guidance with general anesthesia and suspended ventilation during treatment delivery; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Incontinence
Interventions: Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Torrance, California

Conditions: Cirrhosis
Interventions: SYNB1020, Placebo; Drug · Other
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Coronado, California • Rialto, California • Charleston, South Carolina + 2 more

Conditions: Solid Tumors
Interventions: RO7296682, Atezolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression and CVD
Interventions: iHeart Depcare tool; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more

Conditions: Wounded Warrior, Limb Shortening, Amputation
Interventions: Enhanced Fat Grafting, Standard fat graft; Device · Procedure
Lead sponsor: J. Peter Rubin, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neoplasms, Pancreatic
Interventions: GSK3145095, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions: Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more

Conditions: Chronic Pediatric Heart Failure
Interventions: CRT device implant; Device
Lead sponsor: University of Utah; Other
Eligibility: 1 Year to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Delirium, Confusion
Interventions: Confusion Assessment Method, Accelerometer, Commercially available camera, Internet Pod (iPod), Cortisol Swab; Behavioral · Device · Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alcoholic Hepatitis
Interventions: DUR-928 (Moderate AH), DUR-928 (Severe AH); Drug
Lead sponsor: Craig James McClain; Other
Eligibility: 21 Years to 67 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Dementia, Mild Cognitive Impairment (MCI), Cognitively Unimpaired, Alzheimer's Dementia (AD)
Interventions: Elemind Neuromodulation Headband, Exercise Routine; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: ALE.C04, Pembrolizumab; Drug
Lead sponsor: Alentis Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Gilbert, Arizona • Los Angeles, California • New Haven, Connecticut + 4 more

Conditions: Castrate-resistant Prostate Cancer
Interventions: BEZ235, Prednisone, Abiraterone acetate; Drug
Lead sponsor: Charles Ryan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Solid Tumor
Interventions: PEEL-224, FOLF+B; Drug
Lead sponsor: Peel Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more

Conditions: Ovarian Tumors
Interventions: GRN-300, Paclitaxel; Drug
Lead sponsor: Green3Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

A Drug Interaction Study of LY3154207 in Healthy Participants

FE-SaLiR: Function Improvement Exercise

Pain Rehabilitation Virtual Reality (PRVR): Innovations to Enhance Mobility in the Presence of Pain

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

In the Mirror: Functional Appreciated Bodies (IM FAB)

The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

Safety, Tolerability and Pharmacodynamics of SYNB1020

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

A Patient Activation Approach to Implementing Depression Treatment in Cardiac Patients

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

CRT Pilot Study for Children With Heart Failure

Intelligent Intensive Care Unit

DUR-928 in Patients With Alcoholic Hepatitis

Combating Alzheimer's Through Sleep and Exercise

Study of ALE.C04 in Patients With Head and Neck Cancer

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.